SharePost Content Read More Yahoo Finance #finance Post navigation RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24